Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH

NCT01672879 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

259

Enrollment

INDUSTRY

Sponsor class

Conditions

Liver Fibrosis Due to NASH

Interventions

BIOLOGICAL: Placebo
BIOLOGICAL: SIM

Sponsor

Gilead Sciences